ID	PMID	Mutation	Gene/Protein/Region	Encoding Gene/Protein	Disease	Description	Detail
1	31481499	A215T	LF1	LF1	Burkitt Lymphoma		View
2	30546078	G234E	LF1	LF1	Lymphoma, Extranodal NK-T-Cell	R L	View
3	30546078	A241T	LF1	LF1	Lymphoma, Extranodal NK-T-Cell	R L	View
4	31481499	P175L	LF1	LF1	Lymphoma, Extranodal NK-T-Cell		View
5	31481499	R276Q	LF1	LF1	Lymphoma, Extranodal NK-T-Cell		View
6	31481499	W261R	LF1	LF1	Lymphoma, Extranodal NK-T-Cell		View
7	31481499	D6G	LF1	LF1	Nasopharyngeal Carcinoma		View
8	31481499	V49A	LF1	LF1	Nasopharyngeal Carcinoma		View
9	31481499	V49M	LF1	LF1	Nasopharyngeal Carcinoma		View
10	31481499	R243Q	LF1	LF1	Nasopharyngeal Carcinoma Stomach Neoplasms		View
11	31481499	V206A	LF1	LF1	Nasopharyngeal Carcinoma Stomach Neoplasms		View
12	31481499	A241T	LF1	LF1	Nasopharyngeal Carcinoma Stomach Neoplasms Lymphoma, Extranodal NK-T-Cell		View
13	31481499	G234E	LF1	LF1	Nasopharyngeal Carcinoma Stomach Neoplasms Lymphoma, Extranodal NK-T-Cell		View
14	31481499	L324M	LF1	LF1	Nasopharyngeal Carcinoma Stomach Neoplasms Lymphoma, Extranodal NK-T-Cell		View
15	31481499	N185K	LF1	LF1	Nasopharyngeal Carcinoma Stomach Neoplasms Lymphoma, Extranodal NK-T-Cell		View
16	31481499	P306L	LF1	LF1	Nasopharyngeal Carcinoma Stomach Neoplasms Lymphoma, Extranodal NK-T-Cell		View
17	31481499	Q147K	LF1	LF1	Nasopharyngeal Carcinoma Stomach Neoplasms Lymphoma, Extranodal NK-T-Cell		View
18	31481499	Q8H	LF1	LF1	Nasopharyngeal Carcinoma Stomach Neoplasms Lymphoma, Extranodal NK-T-Cell		View
19	31481499	S183Y	LF1	LF1	Nasopharyngeal Carcinoma Stomach Neoplasms Lymphoma, Extranodal NK-T-Cell		View
20	31481499	S314F	LF1	LF1	Nasopharyngeal Carcinoma Stomach Neoplasms Lymphoma, Extranodal NK-T-Cell		View
21	31481499	P306S	LF1	LF1	Stomach Neoplasms		View
22	31481499	T163I	LF1	LF1	Stomach Neoplasms		View

Contents
Description

The table shows all curated mutation sites of EBV in each literature

Table Description Column Note

D
The study mentioned a certain treatment method, such as drug resistance caused by mutations.

G
The study mentioned the virus genotype/subtype information.

R
The study mentioned the reference sequence used for comparison, or the original strain of the virus used for site-directed mutagenesis.

S
The study provided sequence information or accession numbers.

L
The study provided the geographic region/country of data origin.

C
The study provided clinical baseline information.

I
The study involved information related to immune.

T
The study involved host target genes.